Display options
Cite
Kim K, Ahn S, Lim J, et al. Detection of pancreatic cancer biomarkers using mass spectrometry. Cancer Inform. 2015;13:45-53doi: 10.4137/CIN.S16341.
Kim, K., Ahn, S., Lim, J., Yoo, B. C., Hwang, J. H., & Jang, W. (2014). Detection of pancreatic cancer biomarkers using mass spectrometry. Cancer informatics, 1345-53. https://doi.org/10.4137/CIN.S16341
Kim, Kiyoun, et al. "Detection of pancreatic cancer biomarkers using mass spectrometry." Cancer informatics vol. 13 (2014): 45-53. doi: https://doi.org/10.4137/CIN.S16341
Kim K, Ahn S, Lim J, Yoo BC, Hwang JH, Jang W. Detection of pancreatic cancer biomarkers using mass spectrometry. Cancer Inform. 2015 Jan 06;13:45-53. doi: 10.4137/CIN.S16341. eCollection 2014. PMID: 25673969; PMCID: PMC4285963.
Copy Download .nbib Format: NLM
Share it on

Cancer Inform. 2015 Jan 06;13:45-53. doi: 10.4137/CIN.S16341. eCollection 2014.

Detection of pancreatic cancer biomarkers using mass spectrometry.

Cancer informatics

Kiyoun Kim, Soohyun Ahn, Johan Lim, Byong Chul Yoo, Jin-Hyeok Hwang, Woncheol Jang

Affiliations

  1. Department of Statistics, Seoul National University, Seoul, Republic of Korea.
  2. Research Institute and Hospital, National Cancer Center, Goyang, Republic of Korea.
  3. Department of Internal Medicine, Seoul National University Bundang Hospital, Seongman, Republic of Korea.

PMID: 25673969 PMCID: PMC4285963 DOI: 10.4137/CIN.S16341

Abstract

BACKGROUND: Pancreatic cancer is the fourth leading cause of cancer-related deaths. Therefore, in order to improve survival rates, the development of biomarkers for early diagnosis is crucial. Recently, diabetes has been associated with an increased risk of pancreatic cancer. The aims of this study were to search for novel serum biomarkers that could be used for early diagnosis of pancreatic cancer and to identify whether diabetes was a risk factor for this disease.

METHODS: Blood samples were collected from 25 patients with diabetes (control) and 93 patients with pancreatic cancer (including 53 patients with diabetes), and analyzed using matrix-assisted laser desorption/ionization-time of flight mass spectrometry (MALDI-TOF/MS). We performed preprocessing, and various classification methods with imputation were used to replace the missing values. To validate the selection of biomarkers identified in pancreatic cancer patients, we measured biomarker intensity in pancreatic cancer patients with diabetes following surgical resection and compared our results with those from control (diabetes-only) patients.

RESULTS: By using various classification methods, we identified the commonly splitting protein peaks as m/z 1,465, 1,206, and 1,020. In the follow-up study, in which we assessed biomarkers in pancreatic cancer patients with diabetes after surgical resection, we found that the intensities of m/z at 1,465, 1,206, and 1,020 became comparable with those of diabetes-only patients.

Keywords: biomarker; classification; mass spectrometry; pancreatic cancer

References

  1. Cancer Res. 2010 Nov 1;70(21):8309-18 - PubMed
  2. Cancer Inform. 2011 Mar 22;10:65-82 - PubMed
  3. Cancer Epidemiol Biomarkers Prev. 2011 Jan;20(1):140-7 - PubMed
  4. Metabolomics. 2010 Mar;6(1):78-95 - PubMed
  5. Bioinformatics. 2003 Sep 1;19(13):1636-43 - PubMed
  6. Mass Spectrom Rev. 2006 May-Jun;25(3):409-49 - PubMed
  7. Cancers (Basel). 2010 Jun 02;2(2):1107-24 - PubMed
  8. BMC Cancer. 2010 Feb 23;10:55 - PubMed
  9. Gastroenterology. 2005 Aug;129(2):504-11 - PubMed
  10. BMC Bioinformatics. 2008 Jun 11;9:275 - PubMed
  11. BMC Bioinformatics. 2012;13 Suppl 16:S5 - PubMed
  12. Mol Cell Proteomics. 2011 Jul;10(7):M110.004945 - PubMed
  13. CA Cancer J Clin. 2014 Jan-Feb;64(1):9-29 - PubMed
  14. Bioinformatics. 2012 Sep 1;28(17):2270-1 - PubMed
  15. Bioinformatics. 2004 Nov 22;20(17):3034-44 - PubMed
  16. Eur J Cancer. 2011 Sep;47(13):1928-37 - PubMed

Publication Types